Articles From: Genesee & Wyoming Reports Traffic for August 2014 to Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate


Genesee & Wyoming Inc. (G&W) (NYSE:GWR) today reported traffic volumes for August 2014.
Sign-up for Genesee & Wyoming Reports Traffic for August 2014 investment picks
Genesee & Wyoming Inc. (G&W) (NYSE:GWR) today reported traffic volumes for July 2014.
Sign-up for Genesee & Wyoming Reports Traffic for July 2014 investment picks
Genesee & Wyoming Inc. (G&W) (NYSE:GWR) today reported traffic volumes for June 2014 and the second quarter of 2014.
Sign-up for Genesee & Wyoming Reports Traffic for June 2014 and the Second Quarter of 2014 investment picks
Genesee & Wyoming Inc. (G&W) (NYSE:GWR) Chief Financial Officer T.J. Gallagher will present at the Citi Industrials Conference in Boston on Tuesday, Sept.
Sign-up for Genesee & Wyoming to Present at Citi Industrials Conference investment picks
Genesee & Wyoming Inc. (G&W) (NYSE:GWR) Chief Financial Officer T.J. Gallagher will present at the Cowen and Company 7th Annual Global Transportation & Aerospace/Defense Conference in Boston on Wednesday, September 3, 2014, at 1:10 p.m. EDT.
Sign-up for Genesee & Wyoming to Present at Cowen and Company 7th Annual Global Transportation & Aerospace/Defense Conference investment picks
Genesee & Wyoming Inc. (G&W) (NYSE:GWR) Chief Financial Officer T.J. Gallagher will present at the RBC Capital Markets Global Industrials Conference in Las Vegas on Tuesday, Sept.
Sign-up for Genesee & Wyoming to Present at RBC Capital Markets Global Industrials Conference investment picks
2014/8/1
Genesis Announces 2014 Second Quarter Results Conference Call Canada NewsWire SOURCE Genesis Land Development Corp.
Sign-up for Genesis Announces 2014 Second Quarter Results Conference Call investment picks
Genesis Energy, L.P. (NYSE:GEL) announced today that it will pay a regular quarterly distribution of $0.565 per Common Unit for the quarter ended June 30, 2014.
Sign-up for Genesis Energy, L.P. Increases Quarterly Distribution investment picks
Genesis Energy, L.P. (NYSE:GEL) today announced its second quarter results.
Sign-up for Genesis Energy, L.P. Reports Second Quarter 2014 Results investment picks
Genesis Energy, L.P. (NYSE:GEL) will announce its earnings for the second quarter ended June 30, 2014, before the market opens on Thursday, July 31, 2014.
Sign-up for Genesis Energy, L.P. Sets Date for Release of Second Quarter Results and Conference Call investment picks
Genesis Energy, L.P. (NYSE:GEL) announced today that Grant E.
Sign-up for Genesis Energy, L.P. to Participate in Citigroup MLP/Midstream Infrastructure Conference investment picks
http://media.marketwire.com/attachments/201112/37556_Genetic_Technologies_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140136&ProfileId=051205&sourceType=1 MELBOURNE, AUSTRALIA --
Sign-up for Genetic Technologies Announces Further Patent Success in USA investment picks
http://media.marketwire.com/attachments/201112/37556_Genetic_Technologies_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1128963&ProfileId=051205&sourceType=1 MELBOURNE, AUSTRALIA --
Sign-up for Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014 investment picks
Genie Energy Ltd., (NYSE:GNE), a developer of unconventional energy projects and a leading independent retail energy provider, participated in EnerCom’s The Oil and Gas Conference in Denver, CO on August 21 st .
Sign-up for Genie Energy (GNE) at EnerCom’s 2014 The Oil and Gas Conference investment picks
Genie Energy Ltd., (NYSE: GNE), a developer of unconventional energy projects and a leading independent retail energy provider, will present at the Liolios Group’s Third Annual Gateway Conference on September 4, 2014 in San Francisco.
Sign-up for Genie Energy (GNE) to Present at 2014 Gateway Conference investment picks
Genie Energy Ltd., (NYSE:GNE) a leading independent retail energy provider and a developer of unconventional energy projects, will announce financial results for the second quarter of 2014 on Thursday, August 7, 2014.
Sign-up for Genie Energy (GNE) to Report Second Quarter 2014 Results investment picks
Genie Energy Ltd., (NYSE:GNE) a leading independent retail energy provider and a developer of unconventional energy projects, said today that on September 2, 2014, the Jerusalem District Committee for Planning and Building voted to decline to issue Israel Energy Initiatives, Ltd.
Sign-up for Genie Energy Considering Alternative Ways Forward for Oil Shale Pilot Project in Israel investment picks
Genie Energy Ltd., (NYSE:GNE) announced the expiration of its previously disclosed exchange offer of shares of its Class B Common Stock for shares of Series 2012-A Preferred Stock on a one-for-one basis.
Sign-up for Genie Energy Ltd. Completes Exchange Offer investment picks
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced positive preliminary second quarter 2014 results and an update on its NexGen system.
Sign-up for GenMark Announces Positive Preliminary Second Quarter Results investment picks
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the appointment of Dr.
Sign-up for GenMark Diagnostics Appoints Dr. James Fox as Chairman of the Board investment picks
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the quarter ended June 30, 2014.
Sign-up for GenMark Diagnostics Reports Second Quarter 2014 Results investment picks
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Monday, August 11, 2014.
Sign-up for GenMark Diagnostics Schedules Second Quarter 2014 Financial Results Conference Call for August 11, 2014 investment picks
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Canaccord Genuity 34th Annual Growth Conference to be held at the InterContinental Boston Hotel in Boston, MA on Wednesday, August 13, 2014.
Sign-up for GenMark Diagnostics to Present at the Canaccord Genuity 34th Annual Growth Conference investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company’s immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the final dose, in an analysis of an exploratory endpoint, the mean reduction in genital lesion rate was 42 percent below baseline for the best-performing 30 microgram dose group, indicating that GEN-003 may continue to provide a durable effect on genital lesions beyond the six months previously reported.
Sign-up for Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003 investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus ( Streptococcus pneumoniae ), a major cause of infectious disease-related death globally.
Sign-up for Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004 investment picks
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company’s board of directors.
Sign-up for Genocea Appoints Kenneth Bate to its Board of Directors investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock.
Sign-up for Genocea Biosciences, Inc. Commences Public Offering of Common Stock investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to pursue an underwritten public offering of 3,400,000 shares of its common stock.
Sign-up for Genocea Biosciences, Inc. Elects Not to Pursue Public Offering investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2). “Consistent with our long-standing development plans, this Phase 2 trial will compare the best dose of GEN-003 from our Phase 1/2a trial to other combinations of protein and adjuvant to determine the optimal dose for future trials and potentially improve on the current profile of GEN-003,” said Seth Hetherington, MD, chief medical officer of Genocea.
Sign-up for Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy investment picks
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company’s universal vaccine candidate against pneumococcus.
Sign-up for Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Genesee & Wyoming Reports Traffic for August 2014 to Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices